InsiderTrades.com logo
James Aloysius Brady net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Brady Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share

Mr Brady has served as a Non-Executive Director on our board of directors since March 2022.

Mr Brady has extensive experience in the biopharmaceutical industry, serving in multiple leadership roles of increasing responsibility across the US, Europe and China, during his 30-plus-year career at AstraZeneca. Most recently, Mr Brady served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market. Mr Brady currently serves as a Non-Executive Director on the board of Xeris Biopharma Holdings. He is a Certified Public Accountant, holds an MBA from Drexel University and a BS in accounting from St. Joseph University.

What is James Aloysius Brady's net worth?

The estimated net worth of James Aloysius Brady is at least $2.48 million as of August 1st, 2025. Mr. Brady owns 23,176 shares of Verona Pharma PLC American Depositary Share stock worth more than $2,477,746 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Brady may own. Learn More about James Aloysius Brady's net worth.

How do I contact James Aloysius Brady?

The corporate mailing address for Mr. Brady and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on James Aloysius Brady's contact information.

Has James Aloysius Brady been buying or selling shares of Verona Pharma PLC American Depositary Share?

James Aloysius Brady has not been actively trading shares of Verona Pharma PLC American Depositary Share within the last three months. Most recently, James Aloysius Brady sold 824 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $10,827.36. Following the completion of the sale, the director now directly owns 23,176 shares of the company's stock, valued at $304,532.64. Learn More on James Aloysius Brady's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

James Aloysius Brady Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell824$13.14$10,827.3623,176View SEC Filing Icon  
See Full Table

James Aloysius Brady Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows James Aloysius Brady's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05